Item 2.01. Completion of Acquisition or Disposition of Assets.
As previously disclosed in the Current Report on Form 8-K filed by Helix TCS, Inc. (the Company) on March 8, 2018 (the March Form 8-K), the Company and its wholly-owned subsidiary, Helix Acquisition Sub, Inc. (Merger Sub), entered into an Agreement and Plan of Merger (the Merger Agreement) on March 3, 2018 with Bio-Tech Medical Software, Inc. (BioTrackTHC) and Terence J. Ferraro, as the representative of the BioTrackTHC stockholders, pursuant to which MergerSub, subject to the satisfaction or waiver of specified conditions, was to merge with and into BioTrackTHC, with BioTrackTHC surviving the Merger. On June 1, 2018, the Company closed the Merger. Affiliates of Rose Capital Fund I GP, LLC, the manager of RSF4, LLC which owns all of the Companys Series B preferred stock and approximately 1,244,000 shares of Company common stock, received consideration in the Merger on the same terms as all other BioTrackTHC stockholders and as disclosed in the March From 8-K. In connection with closing, the Company also assumed the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan (BioTrackTHC Stock Plan), pursuant to which options exercisable for 8,132,410 shares of Company common stock are outstanding. The foregoing description of the BioTrackTHC Stock Plan is qualified in its entirety by reference to the BioTrackTHC Stock Plan, a copy of which is attached hereto as Exhibit 10.32 and incorporated herein by reference.
For more information on the Merger and the Merger Agreement, see the March Form 8-K, which is incorporated into this Item 2.01 by reference. The Merger Agreement and a copy of the press release regarding the Merger, are filed as Exhibits 2.1 and 99.1, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
